Hypertrophic cardiomyopathy occurs as an autosomal dominant familial disorder or as a sporadic disease without familial involvement. While missense mutations in the ft cardiac myosin heavy chain (MHC) gene account for approximately half of all cases of familial hypertrophic cardiomyopathy, the molecular causes of sporadic hypertrophic cardiomyopathy are unknown.
Introduction
Hypertrophic cardiomyopathy is defined as a primary myocardial disorder (1, 2), characterized by increased ventricular mass with myocyte and myofibrillar disarray (3, 4) , that occurs in the absence of other cardiac or systemic disorders. The diagnosis of hypertrophic cardiomyopathy is based upon the demonstration of unexplained ventricular hypertrophy. Hypertrophy is typically asymmetric, involving the septum and left ventricular free wall (5-7), but may be concentric or confined to the distal left ventricle and/or right ventricle (8) (9) (10) . The familial form of hypertrophic cardiomyopathy is inherited as an autosomal dominant trait (5, (11) (12) (13) (14) . Thus, individuals with familial hypertrophic cardiomyopathy frequently have multiple affected relatives, and must have one affected parent. Sporadic occurrence of hypertrophic cardiomyopathy is defined by similar anatomical and clinical features in an individual whose parents do not have the condition (6, 15) .
Estimation ofthe fraction ofhypertrophic cardiomyopathy that occurs as sporadic disease has been difficult. Two studies using two-dimensional echocardiography in families of probands with at least three available first degree relatives suggested that hypertrophic cardiomyopathy was sporadic in 44% ( 16) and 33% (17) . However, clinical studies tend to overestimate the proportion of sporadic disease for several reasons. First, the severity and distribution of hypertrophy vary considerably, even between related family members, hence assignment of disease status may be inaccurate. Second, there are difficulties ofascertainment in retrospective studies where family members, especially parents, may be deceased or unavailable for study. Third, many ofthe families studied are too small for familial disease to manifest. For these reasons affected relatives may not be identified, with the result that the disease is assumed to be sporadic.
We have previously identified j3 cardiac myosin heavy chain (MHC)' mutations that cause familial hypertrophic cardiomyopathy in about 50% of unrelated families with this disorder ( 18-21 ). Seven different mutations have been identified; all are missense mutations affecting conserved residues in the amino-terminal half of the myosin heavy chain. Knowledge of the particular 3 cardiac MHC gene mutation in a family with hypertrophic cardiomyopathy is of clinical importance, in terms of both diagnosis (20) and prognosis (21 ) .
To investigate the molecular basis ofsporadic hypertrophic cardiomyopathy we screened the ,3 cardiac MHC genes of seven unrelated probands with sporadic hypertrophic cardiomyopathy. Diagnosis was based on the presence oftypical clinical features of the disease in the proband and the absence of disease criteria in both parents. We demonstrate that two of these probands have /3 cardiac MHC mutations that are comparable to those found in patients with familial hypertrophic cardiomyopathy. Genetic analyses ofthe probands' parents reveal that both mutations have arisen de novo, coincident with the appearance of hypertrophic cardiomyopathy.
Methods
Clinical evaluation. After informed consent was obtained in accordance with the Brigham and Women's Hospital Committee for the Protection of Human Subjects from Research Risks, blood was drawn from probands and their first-degree relatives. Clinical, electrocardiographic, and echocardiographic assessments were performed as described previously (22) . The diagnosis of hypertrophic cardiomyopathy was based on the demonstration ofunexplained left, right or biventricular hypertrophy. An individual was diagnosed with sporadic disease if both parents were available for study and lacked criteria for diagnosis of hypertrophic cardiomyopathy.
Detection ofmutations. The techniques used to screen the ft cardiac MHC gene coding sequence for mutations have been described in detail elsewhere (20, 21 ) . The polymerase chain reaction (PCR) was used to amplify # cardiac MHC gene or mRNA sequences from affected individuals' Epstein-Barr virus transformed lymphocytes. Both normal and mutationally altered ft cardiac MHC mRNA was detected by two rounds of PCR amplification. Amplified sequences were hybridized to RNA probes transcribed from a normal gene and RNase A protection assays performed as described previously (20, 21 ) . The entire # cardiac MHC coding sequence was examined in all probands, using both sense and antisense riboprobes.
Amplified DNAs that yielded abnormal RNase cleavage patterns were reanalyzed with new DNA isolates to exclude artifacts arising from PCR, and then subjected to dideoxy nucleotide sequence analysis. Where possible, the nucleotide change identified by sequencing was independently confirmed by demonstration of a predicted change in restriction enzyme site. Amino acid sequences were deduced from DNA sequences.
Genetic analysis offamilies. When a mutation was identified in a proband with sporadic hypertrophic cardiomyopathy its presence was sought in first-degree relatives by either RNase protection assays or restriction enzyme digestion. Paternity was confirmed by demonstration of inheritance of appropriate alleles at eight polymorphic dimeric short tandem repeat sequences (STRs): APOAII, APOCII, ASS, DIS103, DlSl 16, GCG, INT2, and PLA2 (23-29), using PCR conditions as described previously with end-labeled forward primers (23) . Allele frequencies were calculated from a panel of 22 unrelated probands. The parental origin and subsequent inheritance of chromosomes bearing the de novo mutations in the probands was assessed by analysis ofinheritance ofalleles at polymorphisms within the # cardiac MHC gene: dimeric STRs in the 5' untranslated region (30) and in intron 24 (31 ) and the restriction fragment length polymorphism identified by probe pSC14 (32 . This substitution encodes a change from the normal arginine amino acid residue to a cysteine in the mutant polypeptide, and is designated Arg723Cys. Arginine residue 723 is conserved among all known cardiac MHC's and all vertebrate striated muscle MHC's except the human perinatal and rabbit skeletal isoforms (34); mutation to a cysteine residue constitutes a nonconservative substitution with a change in net charge. This missense mutation, which is highly analogous to those others previously described, has not been seen in analyses of more than 180 normal chromosomes. The nucleotide substitution involved in the Arg723Cys mutation is predicted to abolish a BcgI restriction enzyme site present in the normal cDNA sequence. Digestion of amplified cDNA sequences with this enzyme (Fig. 4) confirms the presence of the mutation in individual II-1 and also confirms that all other members ofthe family are genetically unaffected. The paternal relationship of individual 1-1 to 11-1 was confirmed with the eight polymorphic markers, providing odds ofgreater than 100,000 to 1 in favor of paternity. The , cardiac MHC gene polymorphisms were not sufficiently informative in family AR to determine the parental origin of the chromosome that acquired the Arg723Cys mutation. individual I-1 is the biological father of both the proband and her unaffected brother.
The parental origin ofthe chromosome bearing the de novo mutation was assessed by haplotype analysis of the 13 cardiac MHC gene. Polymorphisms in a dimeric STR present in the 5' untranslated region (methods) demonstrate that the chromosome bearing the Glu924Lys mutation in the proband (II-2) was inherited from the father (I-I). This chromosome, which bears a normal copy ofthe 13 
Discussion
These analyses identify two examples of missense mutations in the : cardiac MHC genes of individuals with hypertrophic cardiomyopathy whose parents are clinically and genetically unaffected. We speculate that the 1 cardiac MHC gene mutations in both probands arose in a germline cell as these mutations are expressed in cells ofdifferent lineages, including myocytes and peripheral leukocytes, as well as ovarian germ cells in the proband of family H. Collectively, these data suggest that sporadic hypertrophic cardiomyopathy can result from new mutations that may then be inherited. In one family studied (AR), the affected proband is typical of cases of sporadic hypertrophic cardiomyopathy and no first-degree relatives are clinically or genetically affected. However because there is only a 50% chance that a given chromosome will be inherited by each child, the probability ofa new mutation appearing in the subsequent generation is determined by the number of offspring. Documentation ofgermline mutations is frequently difficult in families of small size. Analyses ofthe H family demonstrated a de novo 13 cardiac MHC gene mutation that is inherited; analyses of generations I and II identify sporadic disease while studies of generations II and III demonstrate a familial pattern. We conclude that de novo 13 cardiac MHC gene mutations can cause sporadic hypertrophic cardiomyopathy; in at least some instances, these new mutations contribute to the incidence of familial hypertrophic cardiomyopathy.
The demonstration of de novo germline mutations in the 13 cardiac MHC gene in individuals with sporadic disease is important in confirming that these mutations are directly responsible for producing hypertrophic cardiomyopathy. In families that coinherit hypertrophic cardiomyopathy and abnormalities ofthe MHC gene, the possibility exists that these abnormalities are merely linked to an unknown gene that is itselfresponsi- Figure 4 . Detection of the Arg723Cys mutation in members of family AR by BcgI restriction enzyme digestion of PCR amplified cDNA. The pedigree is shown above, with symbols as for Fig. 2 . A 500 basepair ,B cardiac MHC cDNA is amplified as previously described, using primers numbered 1925 and 2424 (21 ) . Digestion of a product of normal sequence generates fragments of 320 and 150 bp (arrows). The sample from individual II-1 contains these fragments but also the 500 base-pair fragment (arrow), because the Arg723Cys mutation abolishes the BcgI site on the affected chromosome. This mutation is not present in any other family member. Alternatively, sporadic cases may occur through etiologically distinct mechanisms. Somatic mutations in the fi cardiac MHC gene occurring during embryogenesis that affect the heart progenitor cells but not the germline might be a cause of sporadic disease. Given that such somatic mutations would be unlikely to be expressed in peripheral leukocytes, these would not be detected by the techniques used in this study. Undefined environmental factors might similarly cause a hypertrophic phenotype and contribute to the incidence of sporadic disease.
The finding of de novo mutations in the j3 cardiac MHC gene in individuals with sporadic hypertrophic cardiomyopathy has clinical implications. A genetic diagnosis based on demonstration of a myosin heavy chain mutation should assist in difficult diagnoses. The problems of establishing the clinical diagnosis in individual H 1-1 highlight this issue. Co-existing heart disease, especially hypertension, commonly confounds interpretation of clinical studies, and may prevent the diagnosis, or exclusion, of hypertrophic cardiomyopathy. The findings presented here suggest that the benefits of molecular genetic analysis of the ,3 cardiac MHC gene can be extended to a proportion of cases of sporadic hypertrophic cardiomyopathy. We have previously shown that particular mutations specifically influence survival in familial hypertrophic cardiomyopathy, with nonconservative amino acid substitutions being associated with a worse prognosis (21 ) . In the absence of a family history to predict prognosis, the value of defining the diseasecausing mutation as a prognostic indicator will be especially great in sporadic hypertrophic cardiomyopathy. Moreover, if an individual was not clinically recognized as having sporadic disease the impression of a benign family history may have led to an inappropriate assumption of low risk status.
Genetic counseling for individuals with sporadic hypertrophic cardiomyopathy has not been previously feasible in the absence of an understanding of the etiology of the condition. On the assumption that sporadic disease was a separate, and perhaps nongenetic entity, the risk oftransmission to offspring may have been considered low. Whereas individuals with sporadic hypertrophic cardiomyopathy caused by de novo germline mutations in the f# cardiac MHC gene will transmit the disease gene to 50% of offspring. Once a f# cardiac MHC mutation has been identified in a proband, with either sporadic or familial hypertrophic cardiomyopathy, the possibility exists of prenatal diagnosis or preclinical diagnosis in children.
We conclude that sporadic hypertrophic cardiomyopathy is within the spectrum of familial disease. De novo f3 cardiac MHC gene mutations in germline cells contribute to the incidence of both the sporadic and familial variants of this disorder. Genetic analyses of sporadic cases of hypertrophic cardiomyopathy can help to confirm diagnoses and provide important genetic information to physicians and affected individuals.
